Er:YAG ablative fractional laser-primed photodynamic therapy with methyl aminolevulinate as an alternative treatment option for patients with thin nodular basal cell carcinoma: 12-month follow-up results of a randomized, prospective, comparative trial

Journal of the European Academy of Dermatology and Venereology

Volumn 30, Issue 5, 2016, Pages 783-788

  Choi, S H ^a   Kim, K H ^a   Song, K H ^a  

^a Dong A University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; AMINOLEVULINIC ACID; METHYL 5-AMINOLEVULINATE; PHOTOSENSITIZING AGENT;

ADULT; AGED; ALTERNATIVE MEDICINE; APPLICATION SITE BURNING; BASAL CELL CARCINOMA; BLEEDING; BLISTER; CLINICAL ARTICLE; CONTROLLED STUDY; CRUSTING; ERBIUM YAG LASER; ERYTHEMA; FEMALE; FOAM DRESSING; FOLLOW UP; HISTOLOGY; HUMAN; HYPERPIGMENTATION; ILLUMINATION; KOREAN (PEOPLE); LOCAL SKIN REACTION; MALE; MIDDLE AGED; OCCLUSIVE DRESSING; OOZING; PAIN; PAIN INTENSITY; PATIENT SAFETY; PATIENT SELECTION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REVIEW; SCALE; THERAPY EFFECT; THIN NODULAR BASAL CELL CARCINOMA; TREATMENT RESPONSE; VISUAL ANALOG SCALE; ANALOGS AND DERIVATIVES; CARCINOMA, BASAL CELL; PHOTOCHEMOTHERAPY; SKIN NEOPLASMS; SOLID STATE LASER;

AGED; AMINOLEVULINIC ACID; CARCINOMA, BASAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LASERS, SOLID-STATE; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 84948964566     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13453     Document Type: Review

References (20)

1. Thissen MR, Neumann MH, Schouten LJ,. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999; 135: 1177-1183.
2. Nagore E, Grau C, Molinero J, Fortea JM,. Positive margins in basal cell carcinoma: relationship to clinical features and recurrence risk. A retrospective study of 248 patients. J Eur Acad Dermatol Venereol 2003; 17: 167-170.
3. Ceilley RI, Del Rosso JQ,. Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol 2006; 45: 489-498.
4. Telfer NR, Colver GB, Morton CA,. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008; 159: 35-48.
5. Ross K, Cherpelis B, Lien M, Fenske N,. Spotlighting the role of photodynamic therapy in cutaneous malignancy: an update and expansion. Dermatol Surg 2013; 39: 1733-1744.
6. Braathen LR, Szeimies RM, Basset-Seguin N, et al,. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol 2007; 56: 125-143.
7. Soler AM, Warloe T, Berner A, Giercksky KE,. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage. Br J Dermatol 2001; 145: 467-471.
8. Roozeboom MH, Aardoom MA, Nelemans PJ, et al,. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. J Am Acad Dermatol 2013; 69: 280-287.
9. Lippert J, Smucler R, Vlk M,. Fractional carbon dioxide laser improves nodular basal cell carcinoma treatment with photodynamic therapy with methyl 5-aminolevulinate. Dermatol Surg 2013; 39: 1202-1208.
10. Morton CA, MacKie RM, Whitehurst C, Moore JV, McColl JH,. Photodynamic therapy for basal cell carcinoma: effect of tumor thickness and duration of photosensitizer application on response. Arch Dermatol 1998; 134: 248-249.
11. Horn M, Wolf P, Wulf HC, et al,. Topical methyl aminolevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional therapy. Br J Dermatol 2003; 149: 1242-1249.
12. Tope WD, Menter A, El-Azhary RA, et al,. Comparison of topical methyl aminolevulinate photodynamic therapy versus placebo photodynamic therapy in nodular BCC. J Eur Acad Dermatol Venereol 2004; 18 (Suppl 2): 413-414.
13. Tarstedt M, Rosdahl I, Berne B, Svanberg K, Wennberg AM,. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol 2005; 85: 424-428.
14. Ko DY, Kim KH, Song KH,. A randomised trial comparing methyl aminolaevulinate photodynamic therapy with and without Er:YAG ablative fractional laser treatment in Asian patients with lower extremity Bowen's disease: results from a 12-month follow-up. Br J Dermatol 2014; 170: 165-172.
15. Choi SH, Kim KH, Song KH,. Efficacy of ablative fractional laser-assisted photodynamic therapy for the treatment of actinic cheilitis: 12-month follow-up results of a prospective, randomised, comparative trial. Br J Dermatol 2015; 173: 184-191.
16. Ko DY, Jeon SY, Kim KH, Song KH,. Fractional erbium: YAG laser-assisted photodynamic therapy for facial actinic keratoses: a randomized, comparative, prospective study. J Eur Acad Dermatol Venereol 2013; 28: 1529-1539.
17. Angell-Petersen E, Sørensen R, Warloe T, et al,. Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Invest Dermatol 2006; 126: 265-271.
18. Mikszta JA, Alarcon JB, Brittingham JM, Sutter DE, Pettis RJ, Harvey NG,. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med 2002; 8: 415-419.
19. Goldberg DJ, Berlin AL, Phelps R,. Histologic and ultrastructural analysis of melasma after fractional resurfacing. Lasers Surg Med 2008; 40: 134-138.
20. Soler AM, Warloe T, Tausjo J, et al,. Photodynamic therapy by topicalaminolevulinic acid, dimethylsulphoxide and curettage in nodularbasal cell carcinoma: a one-year follow-up study. Acta Derm Venereol 1999; 79: 204-206.